DistantNews
Support us
Fake Ozempic Sold Online Without Prescription for 'Home Researchers'
🇵🇱 Poland /Health & Science

Fake Ozempic Sold Online Without Prescription for 'Home Researchers'

From Rzeczpospolita · () Polish

Translated from Polish, summarized and contextualized by DistantNews.

At a glance

News Named sources Context piece
  • "Home researchers" are buying semaglutide, the active ingredient in Ozempic, online without a prescription, marketed as peptides for research purposes.
  • These products are sold with dosing instructions and claims of benefits like weight loss, despite manufacturers stating they are for research only and not for human or animal consumption.
  • Websites selling these unregulated semaglutide products often reference Ozempic, leading to confusion and potential misuse by consumers seeking weight loss or diabetes treatment.

Online retailers are marketing semaglutide, the active ingredient in the diabetes and weight-loss drug Ozempic, as research peptides. These products are sold without a prescription, often accompanied by instructions for human use and claims of benefits such as weight reduction. This practice raises concerns about unregulated access to a potent medication.

Semaglutide 2 mg from Bioamino Labs, available in our online store, is the active ingredient of the Ozempic drug, which has gained recognition as an effective agent in the therapy of type 2 diabetes and supporting body weight control.

— peptydyshop.com product descriptionThis quote highlights how a vendor directly links their semaglutide product to the well-known drug Ozempic, emphasizing its therapeutic benefits for diabetes and weight management.

Several websites are offering semaglutide products. For example, peptydyshop.com sells "Semaglutide 2 mg" for 349 Polish zloty, explicitly stating it is the active ingredient in Ozempic and highlighting its use in diabetes and weight control. Despite disclaimers that the product is for research purposes only, the descriptions include extensive details on benefits and dosing, directly referencing Ozempic multiple times. This framing blurs the line between a research chemical and a therapeutic drug.

Although Semaglutide is the active substance, and Ozempic is the trade name of a specific product, both terms are often used interchangeably.

— peptydyshop.com product descriptionThis statement from a product description attempts to equate the generic substance with the brand-name drug, blurring the lines for consumers.

Other vendors employ similar tactics. Twojepeptydy.pl offers "GLP-1+GIP (Ozempic, Tirzepatide) 5mg Slavic Labs" for 399 zloty, marketed as a peptide that suppresses appetite and aids weight loss. Peptology sells "Semaglutide" for 219 zloty, calling it the "gold standard for weight control." While Peptology claims its product is a "research-grade lyophilized peptide" not intended for human use, it directs its offer to "researchers" who may test the substance on themselves, providing information on how it activates natural body mechanisms for appetite suppression and delayed gastric emptying.

One of the most well-known preparations containing Semaglutide is Ozempic.

— peptydyshop.com product descriptionThis quote further reinforces the association between the research chemical and the pharmaceutical drug Ozempic in the vendor's marketing.

Further complicating matters, one-peptides.pl sells semaglutide for 329 zloty as a chemical reagent for research. The seller warns against confusing it with Novo Nordisk's registered Ozempic, Wegovy, and Rybelsus. However, they still include dosing instructions, attributed to a pharmacist with twelve years of experience, ostensibly for informational purposes. Consumers can easily purchase these products online without any verification of their research credentials or intent, highlighting a significant gap in regulatory oversight for substances marketed as research chemicals but intended for self-administration.

Semaglutide – the gold standard of weight control

— peptology.pl product descriptionThis marketing slogan positions the semaglutide product as a leading solution for weight management, despite its intended research use.
DistantNews Editorial

Originally published by Rzeczpospolita in Polish. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog